Modified milk fat reduces plasma triacylglycerol concentrations in normolipidemic men compared with regular milk fat and nonhydrogenated margarine.
BACKGROUND
A modified milk fat with reduced cholesterol was developed by fractionation technology.


OBJECTIVE
The effect of this modified milk fat on the lipoprotein profile of 21 normolipidemic men was compared with that of regular milk fat and nonhydrogenated margarine.


METHODS
A crossover design was used for the administration of the 3 experimental diets, which provided 13240 kJ as 16% protein, 51% carbohydrates, 33-34% lipids, and 21 g fiber/d. The ratio of polyunsaturated to saturated fat was 1.3:1 for the margarine diet and 0.3:1 for the milk-fat diets. The cholesterol content of the modified milk-fat and margarine diets was similar (248 and 254 mg/d, respectively), but was significantly higher (428 mg/d) for the regular milk-fat diet.


RESULTS
Modified and regular milk fats did not change plasma total and LDL cholesterol significantly, but margarine did (P < 0.01). Furthermore, modified milk fat maintained initial HDL(2)-cholesterol concentrations, but margarine reduced this variable significantly (P < 0.05). These results can be explained by the lower ratio of polyunsaturated to saturated fat in the modified and regular milk-fat diets than in the margarine diet. Men who ingested modified milk fat had significantly (P < 0.05) lower total and VLDL-triacylglycerol and VLDL-cholesterol concentrations than did those who ingested either regular milk fat or margarine. This may have been, in part, because of the lower intestinal fat absorption with modified milk fat than with regular milk fat and margarine arising from changes in the melting properties of milk fat with fractionation.


CONCLUSIONS
A reduction in plasma triacylglycerol concentrations after the consumption of modified milk fat may prevent the onset of hypertriacylglycerolemia.
Jacques
H
H
Département des Sciences des Aliments et de Nutrition, Faculté des Sciences de l'Agriculture et de l'Alimentation, Université Laval, Canada. helene.jacques@aln.ulaval.ca
Gascon
A
A
Arul
J
J
Boudreau
A
A
Lavigne
C
C
Bergeron
J
J
D000328:Adult; D000818:Animals; D001053:Apolipoproteins / Q000097:blood; D015992:Body Mass Index; D001835:Body Weight; D002791:Cholesterol, Dietary / Q000008:administration & dosage / Q000032:analysis; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D018592:Cross-Over Studies; D004041:Dietary Fats / Q000008:administration & dosage* / Q000032:analysis; D005227:Fatty Acids / Q000032:analysis; D006801:Humans; D008297:Male; D008383:Margarine / Q000009:adverse effects* / Q000032:analysis; D008892:Milk / Q000009:adverse effects* / Q000737:chemistry; D014280:Triglycerides / Q000097:blood*
D001053:Apolipoproteins; D002791:Cholesterol, Dietary; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004041:Dietary Fats; D005227:Fatty Acids; D014280:Triglycerides; D008383:Margarine